Summary by Futu AI
Apollomics Inc., a biopharmaceutical company based in the Cayman Islands with operations in the United States and China, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024. The company, which focuses on the discovery and development of oncology therapies, has registered Class A Ordinary Shares, Debt Securities, Rights, Warrants, and Units for sale to the public. The registration statement includes a preliminary prospectus detailing the company's business, financials, and the risks associated with investing in its securities. Apollomics Inc. has not specified the amount of securities to be offered or the prices at which they will be sold. The securities may be sold from time to time in one or more offerings...Show More